Development of thrombocytosis in HIV+ drug users: Impact of antiretroviral therapy

M. J. Miguez-Burbano, X. Burbano, Allan E Rodriguez, R. Lecusay, N. Rodriguez, G. Shor-Posner

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

With the exception of hemolytic anemia, the potential hematological toxicity of antiretrovirals (ARV) and combination treatments in HIV treated individuals has not been well established. We report, for the first time, hematological toxicity defined as thrombocytosis in 9% of the HIV+ patients receiving highly active antiretroviral treatment (HAART) being followed in a nutritional clinical trial. Participants were evaluated every 6 months during a 2-year period (1998-2000) and blood drawn for biochemical, hematological and immunological parameters. NK cells were negatively correlated with platelet counts in the total cohort (P = 0.018) and persistently elevated with ARVT. Chronic thrombocytosis was associated with significantly lower NK percentages (P = 0.005). Twenty-five percent of the patients with thrombocytosis developed a cardiovascular disease. Together, these results support the proposal that HAART may increase the risk of hematological dysfunction and impact the risk of cardiovascular disease.

Original languageEnglish
Pages (from-to)183-185
Number of pages3
JournalPlatelets
Volume13
Issue number3
DOIs
StatePublished - Jun 26 2002

Fingerprint

Thrombocytosis
Drug Users
HIV
Cardiovascular Diseases
Hemolytic Anemia
Platelet Count
Natural Killer Cells
Therapeutics
Clinical Trials

ASJC Scopus subject areas

  • Hematology
  • Cell Biology

Cite this

Miguez-Burbano, M. J., Burbano, X., Rodriguez, A. E., Lecusay, R., Rodriguez, N., & Shor-Posner, G. (2002). Development of thrombocytosis in HIV+ drug users: Impact of antiretroviral therapy. Platelets, 13(3), 183-185. https://doi.org/10.1080/0953371027984

Development of thrombocytosis in HIV+ drug users : Impact of antiretroviral therapy. / Miguez-Burbano, M. J.; Burbano, X.; Rodriguez, Allan E; Lecusay, R.; Rodriguez, N.; Shor-Posner, G.

In: Platelets, Vol. 13, No. 3, 26.06.2002, p. 183-185.

Research output: Contribution to journalArticle

Miguez-Burbano, MJ, Burbano, X, Rodriguez, AE, Lecusay, R, Rodriguez, N & Shor-Posner, G 2002, 'Development of thrombocytosis in HIV+ drug users: Impact of antiretroviral therapy', Platelets, vol. 13, no. 3, pp. 183-185. https://doi.org/10.1080/0953371027984
Miguez-Burbano MJ, Burbano X, Rodriguez AE, Lecusay R, Rodriguez N, Shor-Posner G. Development of thrombocytosis in HIV+ drug users: Impact of antiretroviral therapy. Platelets. 2002 Jun 26;13(3):183-185. https://doi.org/10.1080/0953371027984
Miguez-Burbano, M. J. ; Burbano, X. ; Rodriguez, Allan E ; Lecusay, R. ; Rodriguez, N. ; Shor-Posner, G. / Development of thrombocytosis in HIV+ drug users : Impact of antiretroviral therapy. In: Platelets. 2002 ; Vol. 13, No. 3. pp. 183-185.
@article{0ffd8f27019b493d9e6f588b1364a1fb,
title = "Development of thrombocytosis in HIV+ drug users: Impact of antiretroviral therapy",
abstract = "With the exception of hemolytic anemia, the potential hematological toxicity of antiretrovirals (ARV) and combination treatments in HIV treated individuals has not been well established. We report, for the first time, hematological toxicity defined as thrombocytosis in 9{\%} of the HIV+ patients receiving highly active antiretroviral treatment (HAART) being followed in a nutritional clinical trial. Participants were evaluated every 6 months during a 2-year period (1998-2000) and blood drawn for biochemical, hematological and immunological parameters. NK cells were negatively correlated with platelet counts in the total cohort (P = 0.018) and persistently elevated with ARVT. Chronic thrombocytosis was associated with significantly lower NK percentages (P = 0.005). Twenty-five percent of the patients with thrombocytosis developed a cardiovascular disease. Together, these results support the proposal that HAART may increase the risk of hematological dysfunction and impact the risk of cardiovascular disease.",
author = "Miguez-Burbano, {M. J.} and X. Burbano and Rodriguez, {Allan E} and R. Lecusay and N. Rodriguez and G. Shor-Posner",
year = "2002",
month = "6",
day = "26",
doi = "10.1080/0953371027984",
language = "English",
volume = "13",
pages = "183--185",
journal = "Platelets",
issn = "0953-7104",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Development of thrombocytosis in HIV+ drug users

T2 - Impact of antiretroviral therapy

AU - Miguez-Burbano, M. J.

AU - Burbano, X.

AU - Rodriguez, Allan E

AU - Lecusay, R.

AU - Rodriguez, N.

AU - Shor-Posner, G.

PY - 2002/6/26

Y1 - 2002/6/26

N2 - With the exception of hemolytic anemia, the potential hematological toxicity of antiretrovirals (ARV) and combination treatments in HIV treated individuals has not been well established. We report, for the first time, hematological toxicity defined as thrombocytosis in 9% of the HIV+ patients receiving highly active antiretroviral treatment (HAART) being followed in a nutritional clinical trial. Participants were evaluated every 6 months during a 2-year period (1998-2000) and blood drawn for biochemical, hematological and immunological parameters. NK cells were negatively correlated with platelet counts in the total cohort (P = 0.018) and persistently elevated with ARVT. Chronic thrombocytosis was associated with significantly lower NK percentages (P = 0.005). Twenty-five percent of the patients with thrombocytosis developed a cardiovascular disease. Together, these results support the proposal that HAART may increase the risk of hematological dysfunction and impact the risk of cardiovascular disease.

AB - With the exception of hemolytic anemia, the potential hematological toxicity of antiretrovirals (ARV) and combination treatments in HIV treated individuals has not been well established. We report, for the first time, hematological toxicity defined as thrombocytosis in 9% of the HIV+ patients receiving highly active antiretroviral treatment (HAART) being followed in a nutritional clinical trial. Participants were evaluated every 6 months during a 2-year period (1998-2000) and blood drawn for biochemical, hematological and immunological parameters. NK cells were negatively correlated with platelet counts in the total cohort (P = 0.018) and persistently elevated with ARVT. Chronic thrombocytosis was associated with significantly lower NK percentages (P = 0.005). Twenty-five percent of the patients with thrombocytosis developed a cardiovascular disease. Together, these results support the proposal that HAART may increase the risk of hematological dysfunction and impact the risk of cardiovascular disease.

UR - http://www.scopus.com/inward/record.url?scp=0036282444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036282444&partnerID=8YFLogxK

U2 - 10.1080/0953371027984

DO - 10.1080/0953371027984

M3 - Article

C2 - 12180501

AN - SCOPUS:0036282444

VL - 13

SP - 183

EP - 185

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 3

ER -